Search

Introduction: Following the Republic of Korea electric power industry site-specific safety management system, this paper proposes a novel safety autonomous platform (SAP) architecture that can automatically and precisely manage on-site safety through ensemble artificial intelligence (AI) models. The ensemble AI model was generated from video information and worker's biometric information as learning data and the estimation results of this model are based on standard operating procedures of the workplace and safety rules. Methods: The ensemble AI model is designed and implemented by the Hadoop ecosystem with Kafka/NiFi, Spark/Hive, HUE, and ELK (Elasticsearch, Logstash, Kibana). Results: The functional evaluation shows that the main function of this SAP architecture was operated successfully. Discussion: The proposed model is confirmed to work well with safety mobility gateways to provide some safety applications.

BackgroundThe prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay according to age group.MethodsWe identified patients with pN0-1, HR+/HER2− breast cancer in a prospective cohort of women who underwent surgery between 2005 and 2017. The GenesWell BCT assay was performed on tissue samples from selected patients. Distant metastasis-free survival (DMFS) and disease-free survival (DFS) were compared between the risk groups assigned by the BCT score.ResultsA total of 712 patients were eligible for analysis. The median follow-up time was 7.47 years. The BCT score was prognostic in patients aged ≤50 years (n = 404) and those aged >50 years (n = 308). In both age groups, the 10-year DMFS and DFS rates for patients classified as high risk by the BCT score were significantly lower than those for patients classified as low risk. A multivariate analysis revealed that the BCT score was an independent prognostic factor for DFS in patients aged ≤50 years (hazard ratio, 1.28; 95% CI, 1.05–1.56; P = 0.015), as well as those aged >50 years.ConclusionThe BCT score could be used to identify low-risk patients who will not benefit from adjuvant chemotherapy to treat HR+/HER2− early breast cancer regardless of age. A further prospective study to assess the prognostic and predictive value of the BCT score is required.

Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared.Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%) as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer.Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.

As of the end of August 2017, there were 392 academic articles for 4th Industrial Revolution in Korea. Is the vigorous discussion on the 4th Industrial Revolution in Korea normal? We checked the main theories on this topic by existing theories and responses of major countries and industries. The findings are that there are technologies called a Technological Revolution, and the industrial application of some technologies is in the starting stage. If comes, the Industrial Revolution is expected with the structure as follows: excellence science, core technologies, base technologies, application and infrastructure, and institutions. Nonetheless, the brisk studies are from three branches such as the Industry 4.0, social connection and artificial intelligence. The Industry 4.0, the digital transformation of manufacturing is the on-going issue in the industry, and artificial intelligence brings the biggest discourse. The 392 literature are mostly from introduction and preparation for future; technology 15.8%, industry 26.3%, society 24.5%, education 19.1%, policy 10.7%. The labor and employment is only 3.6%. [ABSTRACT FROM AUTHOR]